Virtual Symposium:
Targeted Protein Degradation & PROTAC
16 - 17 February 2021 | GMT (UTC+0)

Advances in Targeted Protein Degradation in target validation, therapeutics development and translation in the clinic.

The programme brings together world leaders from pharmaceutical and biotechnology companies as well as academic institutions to discuss the latest in Targeted Protein Degradation and PROTAC innovation

Download Agenda
Full details on the symposium, including the presentations, topic areas and confirmed speakers can be found in the conference brochure
Book Online

Full Registration is now open for Virtual Symposium: Targeted Protein Degradation & PROTAC. Please click the button below to register for this event.

LinkedIn Group

Our LinkedIn group aims to foster discussion and collaboration between experts working in pathology, biomarker development and translational research.

Headline Sponsor

Thought Leader

Business Developer


The Virtual Symposium: Targeted Protein Degradation & PROTAC includes...

Attendees representing global pharmaceutical organisations, leading biotech companies, internationally renowned academic and healthcare institutions discuss the latest in Targeted Protein Degradation and PROTAC innovation

  • Accelerate discovery & emerging strategies in targeted protein degradation and PROTAC
  • Reconfiguring how drug discovery projects can be approached within the context of Targeted Protein Degradation (TPD)
  • Effective use of mass spectrometry-based proteomics profiling as a discovery tool for understanding the mechanisms of action of drug candidates, including small molecule protein degraders
  • Addressing traditionally undruggable targets in areas of high patient need
  • Successfully degrade intracellular and extracellular targets, leverage the power of the ubiquitin- proteasome system & autophagy-mediated degradation
  • Benefit from the development of degraders from a medicinal chemistry perspective: application of structural biology and rational design strategies
  • Optimizing & Interrogating Protein Structures With Small Molecules, Molecular Glues And PROTAC
  • Gain insights on E3 Ligase Recruiter To Ubiquitinate And Mark Proteins Of Interest For Proteasomal Degradation
  • Optimize PK/PD properties of next generation protein degraders for applications in oncology and beyond

Agenda at a Glance

Day One: 16 February

  • Interrogating Protein Structures With Molecular Glues And Developing New Therapeutic Modalities
  • Developing New Therapeutic Modalities For Targeting The Protein Degradation Machinery
  • Monovalent Degraders/Molecular Glue Degraders
  • Design of Degraders and PROTAC In Cellular Development
  • Bifunction Small Molecules For Degrading Extracellular Proteins
  • Interrogating Protein Structures With Small Molecules, Molecular Glues And PROTACS
  • Protein Degradation Workshop – Development of Degraders From A Medicinal Chemistry Perspective
  • E3 Ligase Recruiter To Ubiquitinate And Mark Proteins Of Interest For Proteasomal Degradation
  • Reimagining Druggability using Chemoproteomic Platforms

Day Two: 17 February

  • Panel Discussion: Protein Degradation – Strategies Beyond The Proof Of Concept Molecules
  • PROTAC- Receptor Kinase Targets & PKPD
  • Protein Degradation For Developing New Targets in Oncology
  • The Impact Of Mass Spectrometry-Based Proteomics For Targeted Protein Degradation
  • Enabling DNA Encoded Libraries as a High Content Discovery Tool for Protein Degradation Molecules
  • Optical Control of Protein Degradation
  • Delivering Clinical Candidate Drugs Using Degraders
  • TRK Degraders for Oncology – New Modality For The Treatment Of Cancer
  • Protein Degradation Seminar Workshop -Translation to the Clinic
  • Optimize PK/PD properties of next generation protein degraders for applications in oncology and beyond
  • Translation Of Protein Degradation Probes Into Safe, Effective Therapeutics

Confirmed Speakers

The Symposium brings together a panel of prominent leaders, engineers and scientists sharing new case studies, innovative data and industry outlook for the future


Georg Winter

CeMM Research Centre for Molecular Medicine


Xavier Jacq

Almac Discovery Ltd


Benedict Cross



Michael Plewe



James Schiemer



Matthew Disney

Scripps Research

Dan Nomura

Daniel Nomura

University of California

Ian Churcher

Ian Churcher

Amphista Therapeutics Limited


Giulia Caron

University of Torino

choudhary, amit

Amit Choudhary

Harvard Medical School

Dirk Trauner

Dirk Trauner



Bin Yang

Kymera Therapeutics

Event Features​

Networking and knowledge Sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of Series features and make the most of participation in a range of virtual, remote experiences. 

Virtual Presentations

Benefit from the insight of our expert speakers via live and pre-recorded presentations

Live Q&As

Interact with fellow attendees and speakers during the live Q&As at the end of each presentation

Digital Networking Opportunities

Connect directly with other registrants of event around the world

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.


Headline Sponsor

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated contract research, development and manufacturing services company serving the global pharma, biotech, nutrition, animal health, consumer goods and specialty chemical sectors.  

Our 4200 scientists have both the skills and the capability to deliver great science, ensure robust data management, IP security and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. 

 With 1.9 Mn sq ft of specialist discovery, development and manufacturing facilities, Syngene offers dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife. We also work with biotech companies pursuing leading edge science, and MNCs including GSK and Merck KGaA.  

We at Syngene have also gained considerable experience in Protein Degradation in recent years.   We currently have a team of 130 FTEs working on the synthesis of PROTACS for various clients, and we have been able to advance several drug candidates to LO and even candidate delivery stage.


Thought Leader Sponsor

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with life-threatening diseases. Our principal technology platform centers on targeted protein degradation, PHM® ‘molecular glues’, that enable the design of small molecules to regulate protein equilibrium. This technology is designed to utilize the body’s own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability to a broad range of diseases, including targets that have to date been considered ‘undruggable’

Wuxi AppTec

Headline Sponsor

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.” 

Over the last five years we have built a comprehensive platform for discovery and characterisation of bifunctional molecules, from initial hit finding activities, through characterisation with biophysical techniques and structural biology, and into in vitro and in vivo functional characterisation and DMPK. This platform is supported by several teams of synthetic organic chemists working across all classes of ligases, ligand and linker chemistries and supporting both optimisation and manufacturing activities.